title: Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
abstract: The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine. A total of 535 patients over 65 years old with a sitting diastolic blood pressure of 90-115 mmHg and/or systolic blood pressure 160-220 mmHg, were recruited at 46 centres worldwide. Patients were randomised to felodipine ER 2.5 mg or amlodipine 5 mg. If blood pressure was > 160/90 mmHg after three or six weeks, felodipine ER was increased to 5 and 10 mg and amlodipine to 10 mg. After nine weeks, average doses of felodipine ER and amlodipine were 5.5 mg and 7.3 mg, respectively. Newly occurring vasodilatory adverse events were reported by 32% of felodipine ER patients and 43% of amlodipine patients (p = 0.007). Both treatments effectively reduced blood pressure 24 hours post-dose. Using a low starting dose and individual titration, felodipine ER achieves good control of blood pressure with few vasodilatory side-effects.
authors.affiliation: University of Munster, Germany.
authors.forename: R M
authors.initials: RM
authors.lastname: Schaefer
authors.forename: P M
authors.initials: PM
authors.lastname: Aldons
authors.forename: E D
authors.initials: ED
authors.lastname: Burgess
authors.forename: R
authors.initials: R
authors.lastname: Tilvis
authors.forename: X
authors.initials: X
authors.lastname: Girerd
authors.forename: G P
authors.initials: GP
authors.lastname: Singh
authors.forename: L
authors.initials: L
authors.lastname: Rehn
authors.forename: T O
authors.initials: TO
authors.lastname: Morgan
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D004487:Edema / Q000139:chemically induced; D015736:Felodipine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D017311:Amlodipine; D015736:Felodipine